Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

84.45CHF
4:31pm GMT
Change (% chg)

CHF-1.80 (-2.09%)
Prev Close
CHF86.25
Open
CHF85.90
Day's High
CHF86.75
Day's Low
CHF83.50
Volume
13,745
Avg. Vol
20,974
52-wk High
CHF150.00
52-wk Low
CHF83.50

Select another date:

Tue, Feb 12 2019

BRIEF-Cosmo Pharmaceuticals Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

BRIEF-Cosmo Pharma Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets With EMA

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

BRIEF-Cosmo Pharmaceuticals: Regulatory Update For Methylene Blue MMX

* NOW IN PROCESS OF FILING A NEW APPEAL TO OFFICE OF NEW DRUGS (OND), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

BRIEF-Cosmo Pharmaceuticals: FDA Grants Approval For Aemcolo (Tm) (Rifamycin)

* FDA GRANTS APPROVAL FOR AEMCOLO (TM) (RIFAMYCIN), THE FIRST APPROVED ANTIBIOTIC TO TREAT TRAVELER'S DIARRHEA FOR TEN YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cassiopea Enters Into Loan Agreement With Cosmo Pharmaceuticals

* COSMO PHARMACEUTICALS HAS OFFERED AN UNSECURED CREDIT LINE OF EUR 10 MILLION THAT CAN BE INCREASED TO EUR 20 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Updates On Type A Meeting Outcome For MB MMX

* METHYLENE BLUE MMX REGULATORY UPDATE: TYPE A MEETING OUTCOME

Select another date: